ArticleCell death & disease2026
PLSCR1 drives chemoresistance in TNBC via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IGF2BP3 promotes glycolysis of osteosarcoma stem cells by reading RNA m⁶A to stabilize ENO1 and promote malignant biological behavior of osteosarcoma.Cell biology and toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) frequently acquires chemoresistance, leading to poor clinical outcomes. Phospholipid scramblase 1 (PLSCR1) has been implicated in breast cancer progression, yet its precise role and underlying mechanisms in TNBC chemoresistance remain elusive. Here, we demonstrate that PLSCR1 is significantly upregulated in chemoresistant TNBC cell lines and patient samples. Mechanistically, PLSCR1 interacts with EGFR, promoting its phosphorylation and subsequent activation of the MAPK signaling pathway, which in turn upregulates the efflux pumps P-gp and MRP1. Concurrently, PLSCR1 mRNA undergoes METTL3-mediated m6A modification, which is recognized by the m6A reader IGF2BP3, leading to enhanced mRNA stability and translational efficiency. Functional studies revealed that PLSCR1 knockdown resensitizes resistant cells to epirubicin, whereas its overexpression exacerbates resistance both in vitro and in vivo. Clinically, elevated PLSCR1 expression correlates with reduced sensitivity to neoadjuvant chemotherapy and poorer prognosis in TNBC patients. Notably, Mogroside IV-A, a specific PLSCR1 inhibitor, effectively overcomes chemoresistance by disrupting PLSCR1-mediated EGFR activation. Collectively, our findings establish PLSCR1 as a critical node integrating the METTL3/IGF2BP3 epigenetic axis with EGFR-MAPK signaling to drive TNBC chemoresistance, and highlight PLSCR1 as a promising therapeutic target for combating drug resistance in TNBC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.